MICA · FIRST-LINE LEARNING NOTES
Understand, prioritise and organise follow-up
An incidental finding needs confirmation, context and risk assessment. Discovery by chance does not automatically imply either harmlessness or an emergency.
Verify the actual finding
Read the full report, method, units, previous values and laboratory or radiologist recommendations. Check patient identity, the original indication and any acute illness. Distinguish an isolated finding from one associated with symptoms or a laboratory critical alert. Premature diagnostic labelling can cause anxiety, repeated investigations and inappropriate surveillance.
[1][2]Confirm without creating a testing cascade
One abnormal creatinine or urine albumin result does not prove chronic kidney disease: examine previous results and possible acute causes, then confirm appropriately. Interpret an unusual TSH with clinical findings, free hormones where indicated and possible interference, including biotin. An incidental adrenal mass requires organised imaging and hormonal assessment; biopsy is not the routine first response.
[1][2][3]Ask whether the result is reliable, urgent and persistent. Verify identity, units, previous values and sampling context. A reduced estimated GFR during acute illness does not establish chronic kidney disease. Discordant thyroid results may require assessment of interference rather than immediate prescribing.
[1][2]Match risk to the appropriate clinician
Refer promptly when a finding accompanies clinical deterioration, organ-specific features or concerning imaging. Incidentaloma decisions depend on the organ, imaging characteristics, cancer history, hormonal function and general health. Some lesions established as benign do not need repeated surveillance; that decision should follow the relevant guideline and be explained to the patient.
[3][1]- A critical result or rapid change requires contacting the patient and arranging appropriate assessment without routine delay.
- For stable non-urgent abnormalities, define confirmatory testing and timing instead of repeating the whole panel.
- Explain uncertainty rather than announcing a definitive disease from one result.
Assign responsibility for follow-up
Record what is confirmed, what remains uncertain and the next action: repeat testing, specialist advice, further investigation or justified discharge from surveillance. Identify who will check completion and results. Explain symptoms requiring earlier review. Explicitly include incidental findings in transfers of care so they are not lost between reports.
[4][1]A learning situation
FICTIONAL CASE · SELF-REFLECTION WITHOUT A SCORE
A 61-year-old woman has CT for renal colic. The report also describes an adrenal lesion requiring characterisation. Her pain has resolved and she assumes no further action is needed because she has no symptoms.
What is the useful next step?
Read the reasoning
Review the exact report and prior imaging, then arrange the recommended characterisation and appropriate hormonal assessment. An incidental lesion may be nonfunctioning or hormone-producing; absence of pain does not determine management. Explain the plan and assign responsibility for checking completion.
References and scope
- Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns ↗
- Thyroid disease: assessment and management (NG145) ↗
- ESE/ENSAT adrenal incidentaloma guideline: official ECE 2023 presentation ↗
- Shared decision making — Recommendations ↗
Original educational synthesis for adult first-line practice. International references must be interpreted with the clinical setting and local care pathways. Independent human scientific review remains to be confirmed.